Renovaro Inc logo

Renovaro Inc

FRA:2Q5 (USA)  
€ 1.42 (+1.87%) Apr 30
At Loss
P/B:
2.40
Market Cap:
€ 211.84M ($ 226.07M)
Enterprise V:
€ 218.51M ($ 233.19M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:

Business Description

Description
Renovaro Inc formerly Renovaro Biosciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Name Current Vs Industry Vs History
Cash-To-Debt 0.03
Equity-to-Asset 0.75
Debt-to-Equity 0.17
Debt-to-EBITDA -0.18
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 10.51
9-Day RSI 16.86
14-Day RSI 25.01
6-1 Month Momentum % -1.56
12-1 Month Momentum % 170.97

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.17
Quick Ratio 0.17
Cash Ratio 0.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11.1
Shareholder Yield % -0.48
Name Current Vs Industry Vs History
ROE % -76.39
ROA % -61.93
ROIC % -30.67
ROC (Joel Greenblatt) % -2818.16
ROCE % -73.19

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 2.4
EV-to-EBIT -5.82
EV-to-EBITDA -5.83
EV-to-FCF -20.12
Earnings Yield (Greenblatt) % -17.19
FCF Yield % -5.07